Announcements Trials
Browse Landscape

Phase

Phase 1 5Phase 2 4Phase 1/2 3

Status

Recruiting 2Terminated 1Active not recruiting 1

Sponsor Class

OTHER 3INDUSTRY 1

Study Type

Interventional 4

Sponsor

Cancer Type

Myeloid 4Other hematologic neoplasm 1

Conditions

Primary Myelofibrosis 13Myeloproliferative Disorders 10Polycythemia Vera 9Leukemia, Myeloid, Acute 9Myelodysplastic Syndromes 6Graft vs Host Disease 6Precursor Cell Lymphoblastic Leukemia-Lymphoma 5Leukemia 5Thrombocythemia, Essential 4Hematologic Neoplasms 4Breast Neoplasms 4Myelodysplastic-Myeloproliferative Diseases 3Leukemia, Myelomonocytic, Chronic 3Leukemia, Myelogenous, Chronic, BCR-ABL Positive 3Recurrence 2Pancreatic Neoplasms 2Neoplasms 2Neoplasm Metastasis 2Lymphoma, T-Cell, Peripheral 2Lymphoma, T-Cell, Cutaneous 2Lymphoma, T-Cell 2Lymphoma, Non-Hodgkin 2Lymphoma 2Leukemia, Myeloid, Chronic-Phase 2Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative 2Leukemia, Monocytic, Acute 2Leukemia, Lymphocytic, Chronic, B-Cell 2Hodgkin Disease 2Colorectal Neoplasms 2Carcinoma, Non-Small-Cell Lung 2

Interventions

fludarabine phosphate 16Cyclophosphamide 15Peripheral Blood Stem Cell Transplantation 10Tacrolimus 9Busulfan 9Whole-Body Irradiation 8Mycophenolic Acid 8fludarabine 6Methotrexate 6Cyclosporine 6Radiotherapy 5ruxolitinib 4Biopsy 4Antilymphocyte Serum 4Specimen Handling 3Decitabine 3peginterferon alfa-2a 2givinostat hydrochloride 2givinostat 2bomedemstat 2Stem Cell Transplantation 2Prednisone 2N-(cyanomethyl)-4-(2-((4-(4-morpholinyl)phenyl)amino)-4-pyrimidinyl)benzamide 2Methylprednisolone 2Melphalan 2Imatinib Mesylate 2Filgrastim 2Etoposide 2Cytarabine 2Aspirin 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Phase 2 × Thrombocythemia, Essential × ruxolitinib × Clear all
NCT04282187 2026-03-16

Decitabine With Ruxolitinib, Fedratinib or Pacritinib for the Treatment of Accelerated/Blast Phase Myeloproliferative Neoplasms

University of Washington

Phase 2 Recruiting
25 enrolled
MyeloidOther hematologic neoplasm

Leukemia, Monocytic, Acute, Myelodysplastic Syndromes, Myeloproliferative Disorders, Polycythemia Vera, Thrombocythemia, Essential, Leukemia, Myeloid, Acute, Myelodysplastic-Myeloproliferative Diseases, Primary Myelofibrosis

NCT04644211 2026-01-08

Ruxolitinib in Thrombocythemia and Polycythemia Vera

Massachusetts General Hospital

Phase 2 Recruiting
60 enrolled
Myeloid

Polycythemia Vera, Thrombocythemia, Essential

NCT02577926 2025-06-10

Ruxo-BEAT

RWTH Aachen University

Phase 2 Active not recruiting
207 enrolled
Myeloid

Polycythemia Vera, Thrombocythemia, Essential

NCT03123588 2021-11-19

Phase 2 Study of Ruxolitinib Versus Anagrelide in Subjects With Essential Thrombocythemia Who Are Resistant to or Intolerant of Hydroxyurea (RESET-272)

Incyte Corporation

Phase 2 Terminated
12 enrolled 15 charts
Myeloid

Myeloproliferative Disorders, Thrombocythemia, Essential

Data powered by HemOnc (CC BY 4.0) Colophon âš¡